Status:
RECRUITING
Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER
Lead Sponsor:
The Netherlands Cancer Institute
Conditions:
Patients With Non-small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intro/rationale: Radiotherapy employs uniform, equally spaced weekday fractions that do not account for changes in tumor radiosensitivity. However, radiobiological characteristics evolve during the ra...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- NSCLC (either pathology proven or sufficient clinical suspicion to be treated as NSCLC), referred for palliative radiotherapy of at least the primary tumor site.
- Stage 2-4
- WHO performance score 0-2.
- Provision of signed, written and dated IC prior to any study specific procedures.
Exclusion
- Interstitial lung disease
- Treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors
- Prior thoracic radiotherapy (\>20 Gy EQD2 a/b 3) overlapping with the current planning target volume
Key Trial Info
Start Date :
August 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2029
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06528743
Start Date
August 8 2024
End Date
August 1 2029
Last Update
January 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Amsterdam, Netherlands